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, poses a major challenge to genetic analysis. To date, no robustly replicated genetic loci have been identified 2 , despite analysis of more than 9,000 cases 3 . Here, using low-coverage whole-genome sequencing of 5,303 Chinese women with recurrent MDD selected to reduce phenotypic heterogeneity, and 5,337 controls screened to exclude MDD, we identified, and subsequently replicated in an independent sample, two loci contributing to risk of MDD on chromosome 10: one near the SIRT1 gene (P 5 2.53 3 10 210 ), the other in an intron of the LHPP gene (P 5 6.45 3 10 212 ). Analysis of 4,509 cases with a severe subtype of MDD, melancholia, yielded an increased genetic signal at the SIRT1 locus. We attribute our success to the recruitment of relatively homogeneous cases with severe illness.
The existence and number of subtypes of depression have been debated over the past 100 years. The current consensus is that depression may be a collection of partly distinct diseases, with overlapping causal pathways. This aetiologic heterogeneity might therefore substantially reduce the power of genetic association studies, and hence explain the failure to find genetic risk loci 3 . For example, there may be cases of MDD of largely environmental origin whose presence reduces the power to detect genetic effects. Also, genetic risk factors for mild depressive syndromes may not be entirely the same as those for more severe cases 4 . For these reasons, we investigated the genetic basis of MDD in subjects for whom known sources of phenotypic and genetic heterogeneity were minimized and known risk factors documented. The CONVERGE (China, Oxford and Virginia Commonwealth University Experimental Research on Genetic Epidemiology) consortium recruited 11,670 Han Chinese women through a collaboration involving 58 hospitals in China. We studied only women because about 45% of the genetic liability to MDD is not shared between sexes 5, 6 . In an attempt to obtain severe cases of MDD, we recruited only recurrent cases (mean number of episodes was 5.6).
We used low-coverage sequencing to genotype our sample 7 . Wholegenome sequences were acquired to a mean depth of 1.73 (95% confidence intervals (CIs) 0.7-4.3) per individual, from which 32,781,340 SNP sites were identified. After applying stringent quality controls (Methods), we obtained 10,640 samples (5,303 cases of MDD, 5,337 controls) and 6,242,619 SNPs for inclusion in genome-wide association studies (GWAS). We compared genotypes from the low-coverage sequencing to genotypes called with 103 coverage sequence and to genotypes called from genotyping arrays and a mass spectrometer platform. The mean percentage concordance between genotypes from nine individuals with both low-and 103 coverage across all sites was 98.1% (Supplementary Table 1) . We compared imputed genotypes to those acquired for 72 individuals using an array and to 21 SNPs genotyped on all individuals with the MassARRAY system mass spectrometer (Supplementary Notes). Overall concordance was 98.0% (Supplementary Tables 2 and 3 ).
Genetic association analysis was carried out with a linear mixed model with a genetic relatedness matrix (GRM) as a random effect and principal components from eigen-decomposition of the GRM as fixed effect covariates (Methods, Supplementary Notes) 8, 9 . Fig. 1a and Extended Data Fig. 1 show the Manhattan and quantile-quantile plots, respectively, for this analysis. The genomic control inflation factor (l, the ratio of the observed median x 2 to that expected by chance) for association with MDD was 1.070 (for common SNPs, minor allele frequency (MAF) .2%, l 5 1.074). The adjusted measure for sample size to that of 1,000 cases and 1,000 controls (l 1000 ) was 1.013.
Two loci exceeded genome-wide significance in association with MDD: one 59 to the sirtuin1 (SIRT1) gene on chromosome 10 (SNP 5 rs12415800, chromosome 10:69624180, MAF 5 45.2%, P 5 1.92 3 10
28
, Fig. 1b) , and the other in an intron of the phospholysine phosphohistidine inorganic pyrophosphate phosphatase (LHPP) gene (SNP 5 rs35936514, chromosome 10:126244970, MAF 5 26.0%, P 5 1.27 3 10 28 , Fig. 1c ). All SNPs with P values of association ,10
25 with MDD are listed in Supplementary Table 4 . We checked the accuracy of the imputed genotypes at 12 SNPs with P , 1 3 10
25
, by re-genotyping the CONVERGE samples using a MassARRAY system mass spectrometer, thereby confirming their association with MDD. Extended Data Table 1 shows that the correlation between the two assays was high (mean r 2 5 0.984), and the odds ratios for the two genome-wide significant SNPs assessed by the two methods were almost identical, with highly overlapping confidence intervals (rs12415800 odds ratios: 1.167 versus 1.167; rs35936514 odds ratios: 0.845 versus 0.842).
We replicated the associations by genotyping the same 12 SNPs in a separate Han Chinese cohort of 3,231 cases with recurrent MDD, and 3,186 controls (both sexes). Two SNPs at the peaks of association for SIRT1 and LHPP loci (rs12415800 and rs35936514, respectively) for MDD in the CONVERGE samples were significantly associated with MDD (Table 1) . Analysis of the combined samples gave P values for association with MDD at these two SNPs of 2.53 3 10 210 and 6.45 3 10
212
, respectively. Extended Data Table 2 shows the genotype distribution and P values for tests of violation of the Hardy-Weinberg equilibrium in both the CONVERGE samples and the replication cohort at both SNPs.
Comparison with results from the Psychiatric Genomics Consortium (PGC) mega-analysis of European studies 3 failed to provide robust replication for our top SNPs (Extended Data Fig. 2 and Extended Data Table 3 ). However, the proportion of associations in the same direction in the two studies exceeded expectations due to chance (P , 0.001), and polygenic risk scores from the PGC megaanalysis applied to the CONVERGE samples were of significant (P , 0.01) but limited predictive value, accounting for 0.1% of MDD risk in the CONVERGE cohort (Extended Data Table 4 ). It is unclear to what extent differences in sample ascertainment, ethnicity, or other factors contribute to the failure to replicate genetic effects in the PGC sample. Notably, variants at our most strongly associated loci are much rarer in European populations, where rs12415800 (SIRT1) and rs35936514 (LHPP) have frequencies of 3% and 8% respectively, compared to 45% and 26% in the CONVERGE cohort.
We considered whether successful mapping of MDD in the CONVERGE samples was attributable to the recruitment of a severe, more genetically determined form of the disease. We tested that hypothesis by looking within the CONVERGE cohort at a particularly severe, and more heritable form of MDD: melancholia 10 . Prior research has suggested that MDD patients with melancholia have more impairing, recurrent episodes and that risk for MDD is higher in the co-twins of probands with the melancholic subtype 11 than in those with non-melancholic MDD. This increase is greater in monozygotic than dizygotic twin pairs 11 , as would be expected if the subtype were associated with greater genetic risk.
In the CONVERGE cohort, 85% of cases met the DSM-IV criteria for melancholia 12 . We searched for a genetic association in 9,846 samples (4,509 cases and 5,337 controls) and identified the same two loci that exceeded genome-wide significance on chromosome 10. The genomic control inflation factor l for melancholia was 1.069, and l 1000 was 1.014. Even though the sample for melancholia was smaller than for MDD, at the SIRT1 locus the significance of association was two orders of magnitude greater than for MDD (top SNP 5 rs80309727, chromosome 10:69617347, MAF 5 45.2%, P 5 2.95 3 10 210 ). Extended Data Fig. 3 shows the Manhattan plot, quantilequantile plot and detailed views of the SIRT1 locus associated with melancholia. All SNPs with P values of association ,10 25 with melancholia are listed in Supplementary Table 5 . To determine whether the increased association might have arisen by chance, we generated an empirical distribution of odds ratios by randomly selecting 4,509 cases from the total set and re-analysing the association with each of the genome-wide significant variants. We found that the observed value lay on the 98.8th percentile at the SIRT1 locus, but at the 61.6 th percentile at the LHPP locus (Extended Data Fig. 4 ). Our results indicate that, as others have suggested 13 , obtaining lowsequence coverage of a large number of individuals can be an effective LETTER RESEARCH way to screen the genome for association signals. We were able to genotype more variants than on genotyping arrays and our set is larger than publicly available sources for imputation 14 . Our imputation pipeline employed standard tools, and it is likely that imputation accuracy could be improved with further algorithmic research.
MDD is most probably highly polygenic 3 , and many additional loci remain to be discovered. We attribute the discovery and replication of two SNPs associated with MDD in the CONVERGE cohort to the recruitment of cases who were probably more homogeneous and more severely impaired than those collected in previous studies from Western cultures. In East Asia, reluctance to report MDD 15 probably explains why hospital-ascertained cases are more severe, and why prevalence estimates for MDD are lower in China (3.6% 16 ) than in the US (16.2%) 17 . Consistent with this interpretation, 85% of the cases of MDD in the CONVERGE cohort have melancholia, a severe subtype of MDD; mapping melancholia led to a significant increase in the genetic signal at one locus. Finally, we note that one of the replicated risk loci is located close to a gene involved in mitochondrial biogenesis (SIRT1) 18 , which, together with our finding that MDD is associated with increased amounts of mitochondrial DNA 19 , suggests an unexpected origin for at least some of the phenotypic manifestations of MDD.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
METHODS
No statistical methods were used to predetermine sample size. Sample collection. CONVERGE collected cases of recurrent major depression from 58 provincial mental health centres and psychiatric departments of general medical hospitals in 45 cities and 23 provinces of China. Controls were recruited from patients undergoing minor surgical procedures at general hospitals (37%) or from local community centres (63%). A sample size of 6,000 cases and 6,000 controls was chosen on the basis of evidence available when the study was designed (in 2007) of the likely existence of genetic loci with odds ratio of 1.2 and above. All subjects were Han Chinese women with four Han Chinese grandparents. Cases were excluded if they had a pre-existing history of bipolar disorder, psychosis or mental retardation. Cases were aged between 30 and 60 and had two or more episodes of MDD meeting DSM-IV criteria 21 with the first episode occurring between 14 and 50 years of age, and had not abused drugs or alcohol before their first depressive episode. All subjects were interviewed using a computerized assessment system. Interviewers were postgraduate medical students, junior psychiatrists or senior nurses, trained by the CONVERGE team for a minimum of 1 week. The diagnosis of MDD was established with the Composite International Diagnostic Interview (CIDI) (WHO lifetime version 2.1; Chinese version), which used DSM-IV criteria. The interview was originally translated into Mandarin by a team of psychiatrists at Shanghai Mental Health Centre, with the translation reviewed and modified by members of the CONVERGE team.
The replication sample was obtained from five hospitals in the north of China. Patients were diagnosed as having MDD by at least two consultant psychiatrists by DSM-IV criteria. Samples were of both sexes, and all four grandparents were Han Chinese. Cases were aged between 30 and 60, and had two or more episodes of MDD meeting DSM-IV criteria. Exclusion criteria were pregnancy, severe medical conditions, abnormal laboratory baseline values, unstable psychiatric features (for example, suicidal), a history of alcoholism or drug abuse, epilepsy, brain trauma with loss of consciousness, neurological illness, or a concomitant axis I psychiatric disorder. Control subjects were recruited from local communities and provided information about medical and family histories. Exclusion criteria were a history of major psychiatric or neurological disorders, psychiatric treatment or drug abuse, or a family history of severe forms of psychiatric disorders.
The study protocol was approved centrally by the Ethical Review Board of Oxford University (Oxford Tropical Research Ethics Committee) and the ethics committees of all participating hospitals in China. All interviewers were mental health professionals who are well able to judge decisional capacity. The study posed minimal risk (an interview and saliva sample). All participants provided their written informed consent. DNA sequencing. DNA was extracted from saliva samples using the Oragene protocol. A barcoded library was constructed for each sample. All saliva samples were randomized in allocation to sequencing batches, and experimenters performing the sequencing procedure were blinded to sample allocation and outcome assessment. Sequencing reads obtained from Illumina Hiseq machines were aligned to Genome Reference Consortium Human Build 37 patch release 5 (GRCh37.p5) with Stampy (v1.0.17) 22 using default parameters after filtering out reads containing adaptor sequences or consisting of more than 50% poor quality (base quality #5) bases. Samtools (v0. 1.18) 23 was used to index the alignments in BAM format 23 , and Picardtools (v1.62) was used to mark PCR duplicates for downstream filtering. The Genome Analysis Toolkit's (GATK, version 2.6) 24 BaseRecalibrator was then run on the BAM files to create base quality score recalibration tables, masking known SNPs and INDELs from dbSNP (version 137, excluding all sites added after version 129). Base quality recalibration (BQSR) was then performed on the BAM files using GATKlite (v2.2.15) 24 while also removing read pairs that did not have the 'properly aligned segment' bit set by Stampy (1-5% of reads per sample). Variant calling. Variant discovery and genotyping at all polymorphic SNPs in the 1000G Phase1 East Asian (ASN) reference panel 14 was performed simultaneously using post-BQSR sequencing reads from all samples using the GATK's UnifiedGenotyper (version 2.7-2-g6bda569). We set the option '--genotype_ likelihood_model' to 'BOTH', used default annotation outputs for variant calls, and set the '--dbSNP' option in order to use dbSNP v137 rsids to fill in the variant ID column of the output variant call format (VCF) files. Variant quality score recalibration was then performed on these sites using the GATK's VariantRecalibrator (version 2.7-2-g6bda569) and the biallelic SNPs from 1000G Phase1 ASN samples as a true positive set of variants. A sensitivity threshold of 90% to SNPs in the 1000G Phase1 ASN panel was applied for SNP selection for imputation after optimizing for Transition to Transversion (TiTv) ratios in SNPs called. This gave a total of 21,356,798 (9,053,391 known in 1000 Genomes Phase 1 ASN Panel and 11,486,024 novel) biallelic SNPs identified from all chromosomes and unassembled contigs. We put forth 20,539,441 SNPs from the autosomes and chromosome X for imputation of genotype probabilities and downstream analyses. Genotype likelihood calculation and imputation. Genotype likelihoods (GLs) were calculated at all 20,539,441 SNPs using a sample-specific binomial mixture model implemented in SNPtools (version 1.0) 25 , and imputation was performed without a reference panel using BEAGLE (version 3.3.2) 26 . We used BEAGLE to perform imputation, using ten iterations on chunks of 3,000 SNPs with 600 SNPs of overlap. A second round of imputation was performed with BEAGLE on the same GLs, but only at biallelic SNPs polymorphic in the 1000G Phase 1 ASN panel using 572 haplotypes from the 1000 Genomes Phase 1 ASN samples as a reference panel for six iterations on chunks containing roughly 3,000 SNPs with 600 SNPs of overlap. After both rounds of imputation we removed the outer 300 SNPs of every window and ligated imputation results of adjacent chunks. A final set of allele dosages and genotype probabilities was generated from these two sets of imputed results by replacing the results in the former with those in the latter at all sites imputed in the latter. We then applied a conservative set of inclusion thresholds for SNPs for GWAS: (a) P value for violation of the Hardy-Weinberg equilibrium .10
26
; (b) information score .0.9; (c) MAF in CONVERGE .0.5%, to arrive at the final set of 6,242,619 SNPs for GWAS. Sample selection for GWAS. Using both processed sequencing data and imputed dosages at SNPs that passed quality control, we assessed the sequencing and imputation quality of all 11,670 samples whose genomic variants we imputed. We first looked into both the nuclear genome and mitochondrial genome for an excess of variants called, since this would indicate cross-sample contamination due to technical issues during sequencing. We quantified the number of singleton variants called in genic regions of the nuclear genome and found a mean of 71.55 private variants per sample that were supported by more than 2 sequencing reads passing sequencing quality controls. We excluded 117 samples with a number of singletons greater than the 99 th percentile. Coverage of the mitochondrial genome was, on average, 1023, allowing us to obtain high-quality sequences for this part of the genome. We found a mean of 15.70 heteroplasmic sites per sample, and 116 samples were found to have greater than the 99th percentile of the number of heteroplasmic sites. Of these 116 samples, 26 were already discarded for having excess nuclear genome singletons; and we excluded the remaining 90.
We then checked imputation quality based on the certainty of genotypes imputed (maximum genotype probability .0.9). We identified 29 individuals who had fewer than 90% of their sites with maximum genotype probabilities .0.9. We excluded these samples from further analysis.
Finally, we assessed the 11,434 remaining samples for genetic relatedness. Although being unrelated to other individuals recruited for the CONVERGE study was a clear criteria in our data collection process, there were instances when the same patient or a relative of the patient visited multiple hospitals and was thus recruited more than once. To exclude duplicates and first-degree relatives from our sample for GWAS, we estimated pairwise genome-wide identity by descent (IBD) using identity by state (IBS) information in hard-called genotypes from imputed genotype probabilities at 399,211 common tagging SNPs across all autosomes (MAF . 1%, linkage disequilibrium (LD) , 0.5, all known in 1000 Genomes Phase 1). We implemented this in PLINK (v1.07) 27 with the option '--genome'. We excluded a total of 392 samples (duplicates and first-degree relatives) from our final set of samples for GWAS. We retained second-degree relatives and beyond, correcting for the relatedness between them using a linear mixed model. We also excluded 402 samples with incomplete phenotype information, giving a final set of 10,640 samples (5,303 cases of MDD, 5,337 controls) for the primary GWAS of MDD. GWAS using linear mixed model and liability score estimates. We implemented MLMA using factored spectrally transformed linear mixed models (FastLMM, v2.06.20130802) 9, 10 and computed one GRM per chromosome using the mixed linear model with candidate marker excluded (MLMe) approach, removing the SNPs from the chromosome in question from a base set of 322,911 common tagging SNPs from all autosomes (MAF . 1%, LD , 0.5, all known in 1000G Phase1 ASN panel) to prevent loss of power through 'double fitting' of the candidate SNP (and those in LD with it) in the GRM as a random effect, while testing each SNP as a fixed effect. Manhattan plots and quantile-quantile plots of the log 10 of P values of the GWAS were generated with custom code in R (ref. 28) . Genomic control inflation factor l was calculated using custom code in R (ref. 28) . Replication and joint analyses. We genotyped the replication sample on a MassARRAY system mass spectrometer. TYPER4.0 was used to assess the reliability of genotype calls generated by SpectroREAD from the mass spectra. Default genotype call inclusion criteria were used. To perform the association analysis with MDD case-control status at these 12 sites in the replication sample, we obtained effect sizes for discovery from logistic regression with principal component (PC) correction, and then for replication from logistic regression, and then performed fixed-effects meta-analysis.
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Polygenic risk profiling and binomial sign-test. Single SNP association results were obtained from the PGC study of MDD 3 . Prior to analysis, SNPs were lifted over to GRCh37/hg19 coordinates and excluded if: (a) monomorphic in either European (n 5 379) or East Asian (n 5 286) populations from the 1000 Genomes Project Phase 1 reference data 14 ; or (b) absent from the filtered CONVERGE data set. To construct the PGC-trained polygenic score, we initially selected autosomal SNPs with statistical imputation information (information score) greater than 0.9 and MAF greater than 1% in both studies, and performed subsequent LD-based 'clumping' to remove markers from highly correlated SNP pairs (pairwise r 2 . 0.2 in East Asians, 500 kb window) while preferentially retaining SNPs with smaller PGC P values. Using the resultant SNP set, we constructed polygene scores based on varying P value thresholds (1 3 10 26 , 1 3 10 25 , 1 3 10 24 , 1 3 10 23 , 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, and 1) as previously described 29 .
We assessed the predictive value of polygenic scores in a genetically unrelated subset of the CONVERGE sample (with pairwise relatedness less than 0.1) by logistic regression, with adjustment for ancestry principal components, demonstrating significant association with MDD status. The estimated variance in MDD risk accounted for by the polygenic score is given by Nagelkerke's R 2 . Using the same P value thresholds, we tabulated the number of independent SNPs with the same direction of allelic effect in the PGC results as observed in CONVERGE. The filtering criteria for SNPs was an information score greater than 0.9 in CONVERGE and MAF greater than 1% in both studies;
and an analogous LD-clumping procedure was performed (pairwise r 2 . 0.2 in Europeans, 500 kb window). A one-sided binomial sign test was used to assess whether this observed fraction was significantly greater than that expected by chance. Results are given in Extended Data Table 4 .
Extended Data Figure 2 | Forest plots of estimated SNP effects in CONVERGE and PGC studies. This figure presents the association odds ratios (OR) at 12 SNPs in CONVERGE and the best available proxy SNPs in PGC-MDD (pairwise r 2 . 0.6, 500 kb window; the proxy SNP is marked by an asterisk). We present the alternative allele frequency (freq), odds ratio (or) with respect to the alternative allele, standard error of odds ratio (se) and P values of association (pval) for the following analyses (study): primary association analysis with a linear-mixed model using imputed allele dosages in 10,640 samples in CONVERGE (pri); validation analysis with logistic regression model with principal components (PCs) as covariates using genotypes from Sequenom on 9,921 samples in CONVERGE (sqnm); association with MDD with a logistic regression model in a replication cohort of 6,417 samples using genotypes from Sequenom (repli); joint association analysis with MDD with a logistic regression model using imputed allele dosages in CONVERGE and genotypes from Sequenom in a replication cohort (17,057 samples in total; joint). samples, equal to the number of cases of MDD not diagnosed as being melancholic. The horizontal axis is the odds ratio for each analysis, and the vertical axis the frequency of occurrence of the odds ratio in 10,000 analyses. The vertical red line is the observed odds ratio after removing cases of MDD not diagnosed as melancholic. Table 2 gives further information on the results for these markers.
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This table shows the number of samples with the homozygous reference genotype (HomRef), heterozygous genotypes (Het), and homozygous alternative genotype (HomAlt), as well as P values for violation of the Hardy-Weinberg equilibrium (HWE) for both CONVERGE study samples and the replication cohort from northern China at the top SNPs rs12415800 in the SIRT1 locus and rs35936514 in the LHPP locus from the GWAS on MDD. The top two rows show these measures for all samples in both the CONVERGE and replication study, the next two rows show these measures for just cases in CONVERGE and the replication cohort, and the last two rows show these measures for just the controls. The genotype distributions for CONVERGE are obtained from hard-called genotypes from maximum imputed genotype probabilities for each sample at each of the two sites. As a genotype will not be called if the maximum genotype probability at a site is lower than 0.9 for any single sample, the total number of CONVERGE samples showing called HomRef/Het/HomAlt genotypes does not equal 10,640 for either SNP. For rs12415800, 19 samples (9 cases, 10 controls) have no genotype calls owing to a maximum genotype probability smaller than 0.9, giving a total of 10,621 CONVERGE (5,294 cases, 5,327 controls) samples with genotype calls. For rs35936514, 87 (39 cases, 48 controls) samples have no genotype calls owing to a maximum genotype probability smaller than 0.9, giving a total of 10,553 (5,264 cases, 5,289 controls) CONVERGE samples with genotype calls.
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Extended Data Table 3 | Single-marker association results of top CONVERGE hits in the PGC study of MDD 
LETTER RESEARCH
Extended Data Table 4 | Polygenic risk profiling and binomial sign tests
The table shows the predictive value of a PGC-trained polygenic risk score on the CONVERGE results. Predictive values are shown at varying P value thresholds (pT) from P # 1 3 10 26 to 1 (that is, all results). P is the P value of the prediction and r 2 is the amount of variance explained (thus the table shows that including all independent SNPs from the PGC study of MDD, irrespective of individual P value, explained 0.09% of MDD risk in CONVERGE.). The number of independent SNPs at each threshold is presented (No. SNPs); the significance of the observed fraction (%) demonstrating a consistent direction of effect was assessed by a one-sided binomial sign test.
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